Methadone News and Research

RSS

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

Correctional policies discourage released inmates from seeking methadone therapy, researchers say

Methadone treatment for opioid dependence remains widely unavailable behind bars in the United States, and many inmates are forced to discontinue this evidence-based therapy, which lessens painful withdrawal symptoms.

30 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine are continuing to drop significantly, falling from 41 per cent of total drug-related deaths in the UK in 2010 to 32 per cent in 2011. Meanwhile, deaths from 'legal highs' - some of which have now been banned - remained steady following a large increase in the previous year.

28 Feb 2013

Education and response programs reduce opioid overdose deaths

Results from a US study suggest that a state-supported program of overdose education and nasal naloxone distribution for potential bystanders can help reduce opioid-related overdose deaths.

8 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Longer looks: A key Hagel mission is to cut military health costs; Medical lessons from a mother's death; How they price - and how we pay for -a $300,000 medicine

As David Brooks and Paul Wolfowitz and many others have shown, it's easy to frame our messy fiscal conundrum in these simple terms of guns vs. butter, or rather, guns vs grandma's buttery-yellow, super-pricey heart medication.

11 Jan 2013

European health officials warn Greece to address increasing number of HIV cases

Officials with the European Centre for Disease Prevention and Control (ECDC) said Greece must act to combat a rising number of HIV cases within high-risk populations, including drug users, or face increased health care costs in the future, Reuters reports.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Offering methadone treatment to drug users significantly reduces HIV infection, transmission risk, study shows

Offering methadone treatment to people who use injection drugs "substantially reduces the risk that they will get HIV or give it to anyone else," according to a BMJ study published this month that pools data from studies done in nine countries, the New York Times reports.

17 Oct 2012

Methadone treatment halves HIV risk

Methadone substitution can significantly reduce the risk for HIV transmission among people who inject opiate drugs, says a team of international researchers.

12 Oct 2012

Opiate substitution therapies linked to reduced risk of HIV transmission

Methadone reduces the risk of HIV transmission in people who inject drugs (PWID), as reported by an international team of researchers in a paper published today in the online edition of the British Medical Journal. This team included Dr. Julie Bruneau from the CHUM Research Centre (CRCHUM) and the Department of Family Medicine at the Universit- de Montr-al.

6 Oct 2012

HIV transmission can be reduced by using opioid substitution treatments instead of injection drug use

People who inject drugs (PWID) can significantly reduce their risk of HIV infection with the use of opiate substitution treatments such as methadone, as suggested by an international team of researchers in a paper published today on bmj.com.

5 Oct 2012

Cholesterol has repercussions for recovering heroin addicts

Cholesterol levels may be negatively associated with heroin craving in patients on methadone maintenance therapy, researchers suggest.

1 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

New research on addiction mutual-support groups

Mutual-help groups for addiction have proliferated, diversified, and adapted to emerging substance-related trends over the past 75 years. A new special, triple issue of the Journal of Groups in Addiction & Recovery - Broadening the Base of Addiction Mutual Support: Bringing Theory and Science to Contemporary Trends - reviews the history of mutual-support groups for addiction that have arisen as adjuncts or alternatives to Twelve Step Programs.

29 Sep 2012

Incentives can help promote drug abstinence among pregnant women with heroin or cocaine addiction

A "contingency management" approach—offering incentives for negative drug tests—can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

1 Sep 2012